← BACK TO $META
$METABull claim
Value Investing with Sven Carlin, Ph.D.Value Investing with Sven Carlin, Ph.D.ANALYSTJul 7, 2026
The claim

“META is fairly priced at 17x earnings with a 9% long-term expected return, making it a relative buy among hyperscalers despite CAPEX risks.”

Why he says it — point by point

FAVORABLE & AGAINST · BOTH KEPT
On record

All in all, fairly priced for 9% return.

Why

the P/E ratio is 17.29

from a relative perspective, it is certainly a buy. 17 versus 30 looks really good.

Risk

they keep on doing the CAPEX for the next 3-4 years and then cancel it, that will be reflected through depreciation and amortization in the net income

the key risk with Facebook is what we already discussed with the CAPEX, but also the unknowns.

The structured call

Direction
Bullish
Catalyst
—
Target
—

The receipt

YouTube · 6:196:19

“META is fairly priced at 17x earnings with a 9% long-term expected return, making it a relative buy among hyperscalers despite CAPEX risks.”

From "When to Buy META Stock!"
Open the source at 6:19 →

Publish-day price $$615.58 · the claim is anchored to the moment it was said.

Others who hold the bull side

3 ON THIS THESIS

The same direction, argued differently — each is its own claim with its own clip.

Mark Roussin, CPAMark Roussin, CPAANALYST

“Meta's valuation is intriguing, though confidence is lower than for Alphabet and Amazon.”

10:43Jose Najarro StocksJose Najarro StocksANALYST

“Meta is a no-brainer buy at a forward PE of 17-18, as fears of AI compute overbuild are overblown and excess capacity can be monetized.”

12:14Joseph Carlson After HoursJoseph Carlson After HoursANALYST

“META is a buy at current levels — 17-18 forward PE, 26% revenue growth, and a discounted narrative create attractive risk/reward, with glasses/AI as long-term catalysts.”

28:22

Value Investing with Sven Carlin, Ph.D. on $META, over time

Full profile →

How this voice has moved on the ticker. We flag contradictions — as behavior, never a score.

This is the only tracked claim from this analyst on the ticker so far.

This receipt is public & free — always.
The full stance archive and CSV export are part of your trial.
This is a record of what one analyst said on one thesis, with the clip — not a recommendation, not a verdict, not a score. The opposing case is linked above.